Knockdown of microRNA‑29a regulates the expression of apoptosis‑related genes in MCF‑7 breast carcinoma cells

Khamisipour,Gholamreza; Mansourabadi,Elham; Naeimi,Behrouz; Moazzeni,Ali; Tahmasebi,Rahim; Hasanpour,Mojtaba; Mosahebi Mohammadi,Majid; Mansourabadi,Zahra; Shamsian,Shakib

doi:10.3892/mco.2017.1528

Knockdown of microRNA‑29a regulates the expression of apoptosis‑related genes in MCF‑7 breast carcinoma cells

Authors:
- Gholamreza Khamisipour
- Elham Mansourabadi
- Behrouz Naeimi
- Ali Moazzeni
- Rahim Tahmasebi
- Mojtaba Hasanpour
- Majid Mosahebi Mohammadi
- Zahra Mansourabadi
- Shakib Shamsian
View Affiliations

Affiliations: Department of Hematology, Faculty of Allied Medicine, Bushehr University of Medical Sciences, Bushehr 75189577, Iran, Student Research Committee, Vice‑Chancellery Research and Technology Affairs, Bushehr University of Medical Sciences, Bushehr 75189577, Iran, Department of Microbiology and Parasitology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr 75189577, Iran, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr 75189577, Iran, Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115331, Iran
Published online on: December 8, 2017 https://doi.org/10.3892/mco.2017.1528
Pages: 362-369

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR), as non-coding small RNA, are key regulators of cancer‑related biological cell processes and contribute to tumor growth through regulation of groups of pro‑ and anti‑apoptotic genes. The present study aimed to investigate the effects of miR‑29a on the expression of genes involved in apoptosis, including p21, B‑cell lymphoma 2 (BCL‑2), p53 and survivin. The MCF‑7 breast cancer cell line was transfected with anti‑miR‑29a and treated with Taxol in subdivided treatment groups including: Scramble; anti‑miR‑29a; anti‑miR‑29a + Taxol; Taxol; and control. Expression levels of p21, BCL‑2, p53 and survivin were evaluated using reverse transcription‑quantitative polymerase chain reaction. miR‑29a knockdown resulted in p21 and p53 upregulation and a decrease in survivin expression. These results indicated that miR‑29a inhibition regulates apoptosis. The present data suggested that miR‑29a inhibition may be a promising strategy for the induction of apoptosis of tumor cells.

View Figures

View References

1	Montazeri A, Vahdaninia M, Harirchi I, Harirchi AM, Sajadian A, Khaleghi F, Ebrahimi M and Haghighat S: Breast cancer in Iran: Need for greater women awareness of warning signs and effective screening methods. Asia Pac Fam Med. 7:62008. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J: Cancer IAfRo: GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC press; 2001
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	Stewart B and Kleihues P: World cancer report. Geneva: International Agency for Research on Cancer. World Health Organization; 2003
5	Khatib OM and Modjtabai A: Guidelines for the early detection and screening of breast cancer: World Health Organization. Regional Office for the Eastern Mediterranean. 2006.
6	Network NCC: NCCN clinical practice guidelines in oncology™ breast cancer: National Comprehensive Cancer Network. 2007.
7	André F and Zielinski CC: Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 23 suppl 6:vi46–vi51. 2012. View Article : Google Scholar : PubMed/NCBI
8	Bauer KM and Hummon AB: Effects of the miR-143/-145 microRNA cluster on the colon cancer proteome and transcriptome. J Proteome Res. 11:4744–4754. 2012. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007. View Article : Google Scholar : PubMed/NCBI
11	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A and Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wu Z, Huang X, Huang X, Zou Q and Guo Y: The inhibitory role of Mir-29 in growth of breast cancer cells. J Exp Clin Cancer Res. 32:982013. View Article : Google Scholar : PubMed/NCBI
14	Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
15	Jiang H, Zhang G, Wu JH and Jiang CP: Diverse roles of miR-29 in cancer (review). Oncol Rep. 31:1509–1516. 2014. View Article : Google Scholar : PubMed/NCBI
16	Letai A: Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest. 115:2648–2655. 2005. View Article : Google Scholar : PubMed/NCBI
17	Plati J, Bucur O and Khosravi-Far R: Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem. 104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI
18	Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:pp. 13944–13949. 2005; View Article : Google Scholar : PubMed/NCBI
19	Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
20	Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP: Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer. 9:862–873. 2009. View Article : Google Scholar : PubMed/NCBI
21	Junttila MR and Evan GI: p53-a Jack of all trades but master of none. Nat Rev Cancer. 9:821–829. 2009. View Article : Google Scholar : PubMed/NCBI
22	Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
23	Xia M, Knezevic D and Vassilev LT: p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Oncogene. 30:346–355. 2011. View Article : Google Scholar : PubMed/NCBI
24	Altieri DC: Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res. 5:447–452. 2003.PubMed/NCBI
25	Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI
26	Hu Y, Xu K and Yagüe E: miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat. 151:269–280. 2015. View Article : Google Scholar : PubMed/NCBI
27	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kanwar JR, Kamalapuram SK and Kanwar RK: Survivin signaling in clinical oncology: A multifaceted dragon. Med Res Rev. 33:765–789. 2013. View Article : Google Scholar : PubMed/NCBI
29	Choghaei E, Khamisipour G, Falahati M, Naeimi B, Mossahebi-Mohammadi M, Tahmasebi R, Hasanpour M, Shamsian S and Hashemi ZS: Knockdown of microRNA-29a changes the expression of heat shock proteins in breast carcinoma MCF-7 cells. Oncol Res. 23:69–78. 2016. View Article : Google Scholar
30	Jolla L: Quantification strategies in real-time PCR Michael W. Pfaffl. 1–112. 2004.
31	Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
32	Park SY, Lee JH, Ha M, Nam JW and Kim VN: miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 16:23–29. 2009. View Article : Google Scholar : PubMed/NCBI
33	Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP and James RJ: Reduced accumulation of specific MicroRNAs in colorectal neoplasia11note: Susan M. O'Connor and Nicholas G. van holst pellekaan contributed equally to this work. Mol Cancer Res. 1:882–891. 2003.PubMed/NCBI
34	Ha TY: MicroRNAs in human diseases: From cancer to cardiovascular disease. Immune Netw. 11:135–454. 2011. View Article : Google Scholar : PubMed/NCBI
35	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
36	Abbas T and Dutta A: p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
37	Warfel NA and El-Deiry WS: p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013. View Article : Google Scholar : PubMed/NCBI
38	Redondo M: Bcl-2, an antiapoptotic gene indicator of good prognosis in breast cancer: The paradox. J Carcinogene Mutagene. 4:135–139. 2013. View Article : Google Scholar
39	Yang J, Cao Y, Sun J and Zhang Y: Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol. 27:1114–1118. 2010. View Article : Google Scholar : PubMed/NCBI
40	Schmidt SM, Schag K, Müller MR, Weck MM, Appel S, Kanz L, Grünebach F and Brossart P: Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 102:571–576. 2003. View Article : Google Scholar : PubMed/NCBI
41	Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M and Sato N: Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 65:11018–11025. 2005. View Article : Google Scholar : PubMed/NCBI
42	Jha K, Shukla M and Pandey M: Survivin expression and targeting in breast cancer. Surg Oncol. 21:125–131. 2012. View Article : Google Scholar : PubMed/NCBI
43	Ghanbari P, Mohseni M, Tabasinezhad M, Yousefi B, Saei AA, Sharifi S, Rashidi MR and Samadi N: Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol. 174:667–681. 2014. View Article : Google Scholar : PubMed/NCBI
44	Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y and Wolfson M: Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ. 9:636–642. 2002. View Article : Google Scholar : PubMed/NCBI